Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
216 Cards in this Set
- Front
- Back
people with mild kidney disease are at greater risk for
|
cardiovascular disease
|
|
4 divisions of kidney disease
|
glomeruli, tubules, interstitium, or blood vessels
|
|
glomerular diseases are most likely to be caused by
|
immunologic reactions
|
|
tubular and interstitial disorders are frequently caused by
|
toxic or infections agents
|
|
azotemia
|
elevation of blood uria nitrogen (BUN) and creatinine levels
|
|
prerenal azotemia
|
hypoperfusion of kidneys; impairs fxn in absence of perenchymal damage
|
|
postrenal azotemia
|
urine flow obstructed beyond kidney
|
|
uremia
|
azotemia associated with a constellation of clinical signs and symptoms and biochemical abnormalities
|
|
frequent secondary manifestations of uremia
|
GI, peripheral nerve, heart involvement
|
|
nephritic syndrome
|
due to glomerular disease and dominated by acute hematuria, mild-moderate proteinuria, and hypertension
|
|
example of classic nephritic syndrome
|
acute poststreptococcal glomerulonephritis
|
|
rapidly progressive glomerulonephritis
|
nephritic syndrome with rapid decline (hours/days) in GFR
|
|
Nephrotic syndrome
|
due to glomerular disease characterized by heavy proteinuria, hypoalbuminemia, severe edema, hyperlipidemia, and lipiduria
|
|
asymptomatic hematuria or proteinuria
|
manifestation of subtle or mild glomerular abnormalities
|
|
acute renal failure
|
dominated by oliguria or anuria, recent onset of azotemia
|
|
what can cause acute renal failure
|
can results from glomerular, interstitial, or vascular/acute tubular injury
|
|
chronic renal failure
|
prolonged symptoms and signs of uremia
|
|
renal tubular defects
|
polyuria, nocturia, electrolyte disorders
|
|
what can cause renal tubular disease
|
directly affect tubular structure (medullary cycstic disease) or cause defects in specific tubular fxns (familial nephogenic diabetes, cystinuria, renal tubular acidosis, lead nephropathy)
|
|
urinary tract infection
|
bacteriuria and pyuria
|
|
pyuria
|
bacteria and leukocytes in urine
|
|
nephrolithiasis (renal stones)
|
severe spasms of pain and hematuria
|
|
4 broad stages of chronic renal failure
|
1) diminished renal reserve (50% normal) 2)renal insuficiency (GFR 20-50% normal) 3) chronic renal failure (GFR 20-25% normal) 4) end-stage renal disease (GFR less than 5% normal)
|
|
what appears in stage 2 of chronic renal failure
|
azotemia, generally with anemia and hypertension
|
|
what appears in stage 3 of chronic renal failure
|
cannot reguate volume and solute composition, dvlp edema, metabolic acidosis, hyperkalemia
|
|
glomerulopathy
|
does not have inflammatory component
|
|
familial disease that often affects glomerulus
|
Fabry disease
|
|
what other things can cause glomerular diseases
|
systemic immunological diseases (Lupus), hypertension, metabolic diseases, other hereditary conditions
|
|
lamina densa
|
thick electron-dense central layer of glomerular basement membrane
|
|
what component are in the glomerular basement membrane
|
collagen (mostly IV), laminin, polyanionic proteoglycans (heparan sulfate), fibronectin, entactin, others
|
|
what is the fxn of collagen IV in the basement membrane
|
network suprasturcture to which other glycoproteins attach
|
|
what domain is important for helix formation and for assembly of collagen monomers into the basement membrane suprastructure
|
NC1 (globular noncollagenous domain at the C terminus)
|
|
building block of collagen network
|
triple helical molecule with 3 alpha chains; each molecule contains 7S domain at N terminus, triple helical domain in middle, and NC1
|
|
what are interdigitating podocyte processes embedded in
|
lamina rara externa of BM
|
|
where are mesangial cells located
|
btwn capillaries in glomerulus
|
|
properties of mesangial cells
|
contractile, phagocytic, able to proliferate, lay down matrix and collagen
|
|
what cell type is mostly responsible for synthesis of glomerular BM
|
podocytes
|
|
slit disphram proteins responsible for permeability
|
nephrin, CD2-associated protein, Podocin
|
|
nephrin
|
transmembrane protein migh large extracellular portion making up Ig-like domains; dimerize across slit diaphragm
|
|
mutations in slit diaphram proteins results in
|
nephrotic syndrome
|
|
hypercellularity is characterized by
|
1) proliferation of mesangial or endothelial cells 2) leukocyte infiltration 3) formation of crescents
|
|
what do crescents consist of
|
accumulations of proliferating parietal epithelial cells and infiltrating leukocytes
|
|
when does cresent formation generally occur
|
following an immune/inflammatory injury
|
|
what molecule is thought to elicite crescent formation
|
fibrin-leaks into urinary space from ruptured BM
|
|
BM thickening 2 forms
|
1) deposition of amorphous electron dense material 2) increased systhesis of protein components
|
|
when does deposition of amorphous electron dense material generally occur
|
immune complex deposition
|
|
when does increased synthesis of protein components causing thickening occur
|
diabetic glomerulosclerosis
|
|
hyalinosis of glomerulus
|
acumulation of material homogeneous and eosinophilic by light microscopy
|
|
what is the hyalin material as seen in electron microscopy
|
extracellular and amorphous made up of plasma proteins insudated from circulation into glomerular structures
|
|
what is hyalinosis a consequence of
|
endothelial or capillary wall injury; end result of various forms of glomerular injury
|
|
sclerosis
|
accumulations of extracellular collagenous matrix
|
|
sclerosis location in diabetic glomerulosclerosis
|
confined to mesangial areas
|
|
what can sclerosis process result in
|
obliteration of some or all of the capillary lumens in affected glomeruli--formation of fibrous adhesions btwn scerotic portions of glomeruli and parietal epithelium and Bowman capsules
|
|
histological classifications of glomerulopathies
|
diffuse, global, focal, segmental; capillary loop or mesangial
|
|
what is found in the majority of patients with glomerulonephritis
|
glomerular deposits of immunoglobulins often with components of complement
|
|
two forms of antibody-associated injury
|
1) antibodies reacting in situ with glomerulus 2) deposition of circulating antigen-antibody complexes
|
|
Heymann nephritis
|
antigen in proximal tubular brush border and antibodies are dvlped against it; membranous nephropathy dvlps
|
|
what occurs once antibodies bind antigen
|
complement activation and shedding of immune aggregates from cell surface to form subepithelial deposits
|
|
what are anti-GBM antibody-induced disease and membraneous nephropathy considered
|
autoimmune diseases
|
|
what are examples of 'planted' antigens
|
cationic molecules like DNA, nucleosomes, other nuclear proteins with an affinity for GBM, bacterial products, free antigen, complement
|
|
anti GBM antibody induced glomerulonephritis
|
antibodies directed against fixed intrinsic antigens that are normal components of the GBM
|
|
pattern of involvement for anti GBM antibody induced glomerulonephritis
|
diffuse linear patterns (unlike Heymann with granular lumpy pattern)
|
|
Goodpasture syndrome
|
antibodies cross react with BM in lung and kidney
|
|
what GBM antigen is responsible for classic anti-GBM induced and goodpasture syndrome
|
component of the noncollagenous domain NC1 of alpha 3 chain of collagen IV
|
|
clinical picture of anti GBM antibody induced glomerulonephritis
|
severe crescentic glomerular damage and rapidly progressive glomerulonephritis
|
|
deposits in the mesangium btwn endothelial cells and GBM
|
subendothelial deposits
|
|
deposits bltwn the outer surface of GBM and podocytes
|
subepithelial deposits
|
|
what occurs when continuous shower of antigen dvlps with repeated cycles of immune complex formation
|
more chronic membraneous or membranoproliferative type of glomerulonephritis
|
|
What factors affect glomerular localization of antigen, antibody, or complexes of both (in circulating complex glomerunephritis)
|
molecular charge, size, glomerular hemodynamics, mesangial fxn, integrity of charge-selective barrier
|
|
where do highly cationic immunogens generally deposit
|
tend to cross GBM and reside in subepithelial location
|
|
where do highly anionic immunogens generally dposit
|
excluded from GBM and trapped subendothialially or not nephrogenic at all
|
|
where neutral charge immunogens generally deposit
|
in mesangium
|
|
alternative complement pathway activation occurs in
|
dense-deposit disease aka membranoproliferative flomerulonephritis (MPGN type II)
|
|
changes in epithelium when injured
|
effaement of foot processes, vacuolization, retraction, detachement from GBM, proteinuria
|
|
neutrophils and monocytes in glomerular injury
|
infiltrate as result of complement activation; realease proteases damaging GBM, free radicals cause cell damage, arachildonic acid reduces GFR
|
|
Macrophages, T lymphocytes, and NK cells in glomerular damage
|
infiltrate in antibody and cell mediated immunity; release large number of biologically active molecules
|
|
Platelets in glomerular damage
|
aggregate and release eicosanoids and GFs
|
|
Resident glomerular cells in glomerular injury
|
stimulated to produce inflammatory mediators
|
|
chemotactic complement components
|
induce leukocyte influx and leads to C5b-C9 formation (membrane attack complex)
|
|
eicosanoids, NO, angiotensin, endothelin
|
involved in hemodynamic changes
|
|
cytokines IL-1 and TNF
|
induce leukocyte adhesion and other effects
|
|
chemokines like monocyte chemoattractant protein 1 and CCL5
|
promote monocyte and lymphocyte influx
|
|
coagulation system
|
fibrin present in glomerulonephritis and may serve as stimulant for crescent formation
|
|
At what GFR does end-stage renal failure proceed at a relatively constant rate independent of original stimulus
|
30-50%
|
|
two major histological characteristics of progressive renal damage
|
focal segmental glomerulosclerosis and tubulointerstitial fibrosis
|
|
focal segmental glomerulosclerosis effects
|
proteinuria; result of adaptation of functioning nephrons
|
|
how can focal segmental glomerulosclerosis be slowed down
|
inhibitors of renin-angiotensin system
|
|
what contributes to progressive injury of focal and segmental glomeruloslerosis
|
inability of mature visceral epithelial cells (podocytes) to proliferate after injury
|
|
tubulointerstitial fibrosis causes
|
ischemia, aute and chronic inflammation, damage/loss of peritubular capillary blood supply
|
|
nephritic syndrome characterized by
|
inflammation to glomeruli
|
|
symptoms of nephritis syndrome
|
hematuria, red cell casts in urine. Azotemia, oliguria, mild/moderate hypertension; proteinuria and edema common, but not as severe
|
|
acute nephrotic syndrome occurs in
|
multisystemic diseases as SLE and microscopic polyangiitis; acute proliferative glomerulonephritis
|
|
most common underlying infection in acute proliferative glomerulonephritis
|
streptococcal
|
|
strains of streptococcal that cause acute proliferative glomerulonephritis
|
B-hemolytic streptococci group A; more than 90% trace to types 12, 4, and 1
|
|
morphology of streptococcal acute proliferative glomerulonephritis
|
enlarged, hypercellular glomeruli (diffuse); granular deposits of IgG, IgM, and C3 in mesangium and along GBM
|
|
clinical outcome of streptococcal acute proliferative glomerulonephritis
|
95% children recover totally; 60% adults recover sporatically
|
|
Rapidly progressive (crescentic) glomerulonephritis (RPGN)
|
associated with severe glomerular injury and does not denote a specific etiologic form of glomerulonephritis; generally immunologic
|
|
3 types of RPGN
|
1) anti-GBM antibody-induced 2) immune complex deposition 3) lack of anti-GBM antibodies or immune complexes (pauci-immune type)
|
|
characteristics of anti-GBM antibody induced RPGN
|
linear deposits of IgG and many times C3 in GBM
|
|
treatment of anti-GBM antibody induced RPGN
|
plasmapheresis to remove circulating antibodies as well as therapy to suppress underlying immune response
|
|
goodpasture antigen
|
peptide within noncollagenous portion of alpa 3 chain of collagen IV
|
|
what is present in the 3rd type of RPGN
|
circulating antineutrophil cytoplasmic antibodies (ANCAs); 90% of idiopathic cases contain
|
|
what is the target antigen of most p-ANCAs
|
myeloperoxidase
|
|
morphology of RPGN
|
kidneys enlarged and pale, petechial hemorrhages, distinctive crescents, fibrin strands frequently prominent; ruptures in GBM
|
|
clinical course of RPGN
|
hematuria, red blood cell casts in urine, moderate proteinuria, variable hypertension and edema
|
|
nephrotic syndrome maifestations
|
massive proteinuria (3.5 g daily), hypoalbuminemia, generalized edema, hyperlipidemia and lipiduria
|
|
initial event in nephrotic syndrome
|
derrangement in glomerular capillaries resulting in increased permeability to plasma proteins
|
|
highly selective proteinuria
|
mostly low MW proteins like albumin 70 kD and transferrin 76 kD
|
|
why does hyperlipidemia result in neprotic syndrome
|
increase synthesis of lipoproteins in liver, abnormal transport of circulating lipid particles, and decreased catabolism
|
|
oval fat bodies
|
lipoprotein resorbed by tubular cells and then shed along with degenerated cells
|
|
what infections are nephrotic patients vulnerable to and why
|
staph and pneumococcal; loss of immunoglobulins in urine
|
|
why are thrombotic and thromboembolitic complications present in neprotic syndrome
|
loss of endogenous anticoagulants and antiplasmins in urine (antithrombin III)
|
|
usual cause of nephrotic syndrome if under 17 in north america
|
lesion primary to kidney
|
|
most frequent systemic causes of nephrotic syndrome
|
diabetes, amyloidosis, SLE
|
|
membranous nephropathy
|
common cause of nephrotic syndrome in adults; diffuse thickening of glomerular capillary wall due to accumulation of electron-dense Ig-containing deposits along subepithelial side of BM
|
|
secondary membranous nephropathy causes
|
drugs, underlying malignant tumors, SLE, infections, other autoimmune diseases (thyroiditis)
|
|
what percentafe of membranous nephropathy is idiopathic
|
~85%
|
|
how does glomerular capillary wall become leaky in membranous glomerulopathy
|
direct action of C5b-C9 (formation of membrane attack complex)
|
|
morphology of membranous nephropathy
|
normal in early stages or uniform diffuse thickening or glomerular capillary wall; IgG and complement present; sclerosis as progresses
|
|
what is difference in proteinuria of membranous nephropathy and minimal-change disease
|
it is non-selective and doesn't respond well to corticosteroid therapy
|
|
minimal-cahnge disease
|
relatively benign disorder that is most frequent cause of nephrotic syndrome in children
|
|
minimal-change disease characteristics
|
diffuse effacement of foot processes if visceral epithelial cells in glomeruli that applear virtually normal by light microscope; no Ig or complement deposits
|
|
most characterisitc feature of minimal-change disease
|
dramatic response to corticosteroid therapy
|
|
what contributes to proteinuria in minimal-change diease
|
defects in charge barrier
|
|
possible protein defects in minimal change disease (either genetic or immune related)
|
nephrin, podocin
|
|
what other proteinuric states cuase foot process effacement besides minimal change disease
|
membranous glomerulopathy, diabteic nephropathy
|
|
when can minimal change disease be diagnosed
|
only when effacement is associated with normal glomeruli by light microscope
|
|
what are proximal tubules often laiden with in minimal-change disease
|
lipid and protein (lippoid nephrosis is old name for this disease)
|
|
what can minimal change disease be associated with in adults
|
Hodgkin lymphoa and sometimes other lymphomas and leukemias
|
|
What does focal segmental glomerulosclerosis frequently manifest with clinically
|
nephrotic syndrome or heavy proteinuria
|
|
When does focal segmental glomerulosclerosis occur
|
1) primary disease (idiopathic) 2) association with other diseases 3) secondary event (scarring of previously active necrotizing lesions) 4) cocmponent of adaptive response 5) uncommon inherited forms
|
|
example of focal segmental glomerulosclerosis in association with other known conditions
|
HIV infection, sickle-cell disease, massive obesity
|
|
example of focal segmental glomerulosclerosis as a secondary event
|
focal glomerulonephritis (IgA nephropathy)
|
|
What genetic mutation can cause focal segmental glomerulosclerosis
|
proteins localized to slit diaphram like podocin, alpha-actinin, and TRPC6
|
|
how does FSGS differ from minimal change disease
|
1) higher incidence of hematuria, reduced GFR, and hypertension 2) proteinuria often more selective 3) poor response to corticosteroid therapy 4) progression to chronic kidney disease; at least 50% dvlp end stage within 10 years
|
|
Is FSGS a disinct disease?
|
may be a phase of a subset of minimal-change disease patients
|
|
What is the hallmark of FSGS
|
epithelial damage (caused by multiple mechanisms)
|
|
what makes circulating cytokines suspect of epithelial damage in FSGS
|
recurrence of proteinuria, sometimes within 24 hours after transplantation
|
|
what do the lesions in FSGS tend to initially involve
|
Juxtamedullary glomeruli, then become generalized
|
|
what occurs in sclerotic segments in FSGS
|
collapse of capillary loops, increase in matrix, and segmental deposition of plasma proteins along capillary wall (hyalinosis)
|
|
morphologic variant of FSGS
|
collapsing glomerulopathy
|
|
collapsing glomerulopathy
|
retraction of the entire glomerular tuft with or without FSGS lesions; HIV associated; poor prognosis
|
|
what gene encodes nephrin
|
NPHS1 on chromosome 19q13
|
|
what is nephrin
|
key component of slit diaphragm; zipper-like structure btwn podocyte foot processes that may control permeability
|
|
what does a mutation in nephrin cause
|
congenital nephrotic syndrome; a minimal-change disease
|
|
What is the gene for podocin
|
NPHS2 on chromosome 1q25-q31
|
|
What are the effects of a podocin mutation
|
syndrome of steroid-resistant nephrotic syndrome of childhood onset
|
|
What may TRPC6 cause in adult onset FSGS be caused from
|
perturb podocyte fxn by increasing calcium influx
|
|
when does renal ablation FSGS occur
|
complication of glomerular and nonglomerular diseases casuding reduction in fxning renal tissue
|
|
clinical course of FSGS
|
little spontaneous remission in idiopathic form, corticosteroid response variable; reoccurs in 25-50% patients receiving allografts
|
|
Morphologic features of HIV associated renal complications
|
high frequency of collapsing variant FSGS, striking focal cystic dilation of tubule segments, presence of large numbers of tubuloreticular inclusions within endothelial cells
|
|
what is present with the striking focal cystic dilation of tubule segments
|
filled with proteinaceous material, and inflammation and fibrosis
|
|
what are the tubuloreticular inclusions within endothelial cells modifications of
|
ER induced by circulating interferon-alpha; not present in idiopatic FSGS
|
|
What HIV gene products may cause renal complications
|
vpr and nef expression by podocytes; may also be caused by systemic release of cytokines
|
|
membranoproliferative glomerulonephritis (MPGN) histology
|
alterations in alomerular BM, proliferation of glomerular cells, and leukocyte infiltration
|
|
where is proliferation dominant in MPGN
|
mesangium, but may involve capillary loops; MPGN also called mesangiocapillary glomerulonephritis
|
|
what percent of nephrotic cases in children and young adults are MPGN
|
10-20%
|
|
Two major types of primary MPGN
|
type I and II
|
|
type I MPGN
|
evidence of immune complexes in glomerulus and activation of both classic and alternative complement pathways; unknown antigens
|
|
what are antigens in many cases of MPGN believed to come from
|
proteins from hep C and B
|
|
type II MPGN (dense-deposit disease)
|
activation of alternative complement pathway; decreased serum C3, normal C1 and C4; diminished fator B and properdin
|
|
what circulating antibody is found in 70% of MPGN type II
|
C3 nephritic factor (C3NeF); autoantibody that binds to the alternative pathway C3 convertase stabilizing it
|
|
what genetically determined disease can cause MPGN type II
|
partial lipodystrophy
|
|
MPGN type I and II morphology
|
large and hypercellular; sometimes crescents; glomeruli lobular due to proliferation; GBM thickened; glomeruar capillaty wall has tram-track appearance
|
|
type I MPGN morphology different from type II
|
discrete subendothelial electron-dense deposits; mesangial and occasional subepithelial deposits may be present; C3 deposited in granular pattern; IgG and early complement proteins often present
|
|
type II MPGN morphology different from type I
|
lamina densa of GBM transformmed into an irregular, ribbon-like, extremely electron-dense structure due to deposition of unknown dense material in GBM proper; C3 present in irregular granular or linear foci in BMs; C3 also in mesangial rings; IgG ususally absent as are early complement components
|
|
how does MPGN present clinically
|
adolescent/young adult with nephrotic syndrome with nephritic component manifested by hematuria or mild proteinuria
|
|
MPGN progression
|
few spontaneous remissions, slowlyprogressive and unrelenting course; 50% chronic renal failure in 10 years
|
|
what occurs to MPGN patients with allograft
|
up to 90% reoccurance, although renal failure less common
|
|
When does secondary MPGN arise in adults
|
1) chronic immune complex disorders 2) alpha1-antitrypsin deficiency 3) malignant diseases 4) hereditary deficiencies of complement regulatory proteins
|
|
IgA nephropathy (Berger disease) is characterized by
|
presence of prominent IgA deposits in mesangial regions
|
|
What is the most common glomerulonephritis worldwide
|
IgA nephropathy; frequent cause of recurrent gross or microscopic hematuria
|
|
what can patients with IgA nephropathy present with
|
mild proteinuria, nephrotic syndrome occasionally, rarely with cresentic RPGN
|
|
Henoch-Schonlein purpura
|
systemic disorder in children similar to IgA nephropathy
|
|
when can secondary IgA nephropathy dvlp
|
liver and intestinal diseases
|
|
what is IgA the main Ig secretion of
|
mucosal secretions
|
|
What subclass of IgA molecules in humans causes neprogenic deposits of IgA
|
IgA1
|
|
what complement acivation occurs in IgA nephropathy
|
presence of C3 without C1q and C4, indicating alternative activation
|
|
When does IgA nephropathy have an increased frequency of occurance
|
gluten enteropathy (celiac disease); liver disease where there is decreased clearance of IgA complexes
|
|
What may cause autoimmunity against IgA
|
defect in galactosylation
|
|
clinical outcome for IgA nephropathy
|
highly variable; hematuria for several days that subsides, then returns every few months; slow progression to chronic renal failure over 20 years in 15-40%
|
|
what is outcome of allograft in IgA nephropathy
|
reoccurance frequent and in 15% follows same progressive course
|
|
Alport syndrome maifestations
|
hematuria with progression to chonic renal failure accompanied by nerve deafness and varius eye disorders
|
|
how is alport inherited
|
X-linked; are some autosomal recessive and dominant pedigrees
|
|
what causes alport
|
abnormal COL4A3, COL4A4, or COL4A5 of type 4 collagen
|
|
which mutation causes the classic X-linked form
|
COL4A5 (alpha 5)
|
|
what does the alpha 3 chain contain (COL4A3)
|
Goodpasture antigen
|
|
Morphology of alport
|
glomeruli always involved; difuse GBM thinning; interstitial foam cells; focal segmental and global glomerulosclerosis as progresses
|
|
Thin BM lesion (benign familial hematuria)
|
diffuse thining og GBM to 150-250 nm (normally 300-400 nm);
|
|
Outcome of thin BM lesion
|
mild-moderate proteinuria; renal fxn is normal and prognosis is excellent
|
|
what causes thin M lesion (benign familial hematuria)
|
defect in collagen type 4; may be more progressive is homozygous or cmpd herterozygous
|
|
chronic glomerulonephritis
|
pool of end-stage glomerular disease fed by several streams of specific types of glomerulonephritis
|
|
morphology of chronic glomerulonephritis
|
kidneys symmetrically contracted, diffuse granular coritcal surfaces; cortex is thinned with increase in peripelvic fat; oblitertation of glomeruli; hypertension
|
|
what are common dialysis changes seen in kidneys that are unrelated to the primary disease
|
arterial intimal thickening, extensive deposition of calcium oxalate crystals, aquired cystic disease
|
|
what do the obliterated glomeruli contain
|
acellular eosinophilic masses with trapped plasma proteins, increased mesangial matrix, BM-like material, and collagen
|
|
common uremic complications in chronic renal failure
|
pericarditis, uremic gastroenteritis, secondary hyperparathyroidism, L ventricular hypertrophy, pulmonary changes
|
|
what are pulmunary changes generally caused by
|
uremia that causes diffuse alveolar damage (uremic pneumonitis)
|
|
lupus nephritis clinical maifestations
|
recurrent micoscopic or gross hematuria, nephritic syndrome, nephrotic syndrome, chronic renal failure, hypertension
|
|
henoch-schonlein purpura consists of
|
purpuric skin lesions involving exstensor surfaces, abdomen, nonmigratory arthralgia, renal abnormalities
|
|
henoch-schonlein purpura renal abnormalities
|
1/3 occurance; gross or microscopic hematuria, nephritis syndrome, nephrotic syndrome, or combination
|
|
what disease may be the same as henoch-schonlein purpura
|
IgA nephropathy
|
|
bacterial endocarditis associated glomerulonephritis
|
immune complex nephritis initiated by complexes of bacterial antigen and antibody
|
|
diabetic nephropathy occurance
|
advanced/end-stage in up to 40%; most commonly involve glomeruli
|
|
3 glomerular syndromes in diabetic nephropathy
|
non-nephrotic proteinuria, nephrotic syndrome, and chronic renal failure
|
|
what else does diabetes affect in kidneys
|
arterioles--increase susceptability to pyelonephritis, papillary necrosis, and a variety of tubular lesions
|
|
morphologic glomeruli changes in diabetes
|
1) capillary BM thickening 2) diffuse mesangial sclerosis 3) nodular glomerulosclerosis
|
|
metabolic defect in diabetes that cause renal issues
|
metabolic defect: insulin deficiency, hyperglycemia, some other glucose intolerance aspect
|
|
other issues in diabetes that contribute to renal diseases
|
nonenzymatic glycosylation of proteins, hemodynamic changes
|
|
amyloidosis
|
deposits of amyloid within slomeruli; generally of light-chain (AL) or AA type
|
|
what do patients with amyloidosis present with
|
nephrotic syndrome and may later die of uremia
|
|
fibrillary glomerulonephritis
|
morphologic variant of glomerulonephritis associated with characteristic fibrillar deposirs in mesangium and glomerular capillary walls that resemble amyloid fibrils superficially but don't stain with Congo red
|
|
deposition of what Ig in fibrillary glomerulonephritis
|
polycolonal IgG, often IgG4 subclass, complement C3, Igk and Igdelta light chains
|
|
size of fibrous material in fibrillary glomerulonephritis vs amyloidosis
|
18-24 nm vs 10-12 nm
|
|
what is clinical picture of fibrillary glomerulonephritis
|
nephrotic syndrome, hematuria, progressive renal insufficiency; reoccurs in allograft
|
|
immunotacoid glomerulopathy
|
deposits are microtubular in structure 30-50 nm width; circulating paraproteins and/or monoclonal Ig deposition in glomeruli
|
|
essential mixed cryglobulinemia
|
systemic condition in which deposits of cryoglobins composed of IgG-IgM complexes induce cutaneous vasculitis, synovitis, and proliferative glomerulonephritis (typically MPGN); associated with hep C
|